New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy
ÌÇÐÄ´«Ã½
Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy BJU INTERNATIONAL Sonpavde, G., Khan, M. M., Svatek, R. S., Lee, R., Novara, G., Tilki, D., Lerner, S. P., Amiel, G. E., Skinner, E., Karakiewicz, P. I., Bastian, P. J., Kassouf, W., Fritsche, H., Izawa, J. I., Ficarra, V., Dinney, C. P., Lotan, Y., Fradet, Y., Shariat, S. F. 2011; 108 (5): 687-692Abstract
• To stratify risk of pathological (p) T2N0 urothelial carcinoma of the bladder after radical cystectomy (RC) based on pathological factors to facilitate the development of adjuvant therapy trials for high-risk patients.• The study comprised 707 patients from a database of patients with pT2N0 urothelial carcinoma of the bladder who had undergone RC and not received perioperative chemotherapy. • The effect of residual pT-stage at RC, age, grade, lymphovascular invasion and number of lymph nodes removed on recurrence-free survival was evaluated using Cox regression analyses. A weighted prognostic model was devised with significant variables.• The median follow up was 60.9 months. In multivariable analyses, residual disease at RC (pT2a: hazard ratio (HR) 1.740, P = 0.03; for pT2b: HR 3.075, P < 0.001; both compared with
View details for
View details for
View details for